1. Home
  2. QQQX vs TYRA Comparison

QQQX vs TYRA Comparison

Compare QQQX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

QQQX

Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

N/A

Current Price

$25.57

Market Cap

1.5B

Sector

Finance

ML Signal

N/A

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$20.09

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QQQX
TYRA
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
QQQX
TYRA
Price
$25.57
$20.09
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
★ $47.45
AVG Volume (30 Days)
102.6K
★ 530.2K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
★ 7.03%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.35
$18.25
52 Week High
$31.87
$40.65

Technical Indicators

Market Signals
Indicator
QQQX
TYRA
Relative Strength Index (RSI) 23.15 43.93
Support Level $25.35 $18.46
Resistance Level $31.11 $22.69
Average True Range (ATR) 0.80 1.15
MACD -0.34 -0.08
Stochastic Oscillator 2.09 19.25

Price Performance

Historical Comparison
QQQX
TYRA

About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest

Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets (as defined below) in a diversified equity portfolio made up of securities comprising the S&P 500 Index (or securities that have economic characteristics that are similar to those securities comprising the S&P 500 Index) that seeks to substantially replicate price movements of the S&P 500 Index and is designed to support the Fund's option strategy.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: